The Clinical Features and Emotional Stressors in Korean Patients with Tako-Tsubo Cardiomyopathy

Table 4

The comparison of clinical courses and management between the subgroups.

	Total (n = 103)	E group (n = 15)	Other group (n = 88)	P
Use of inotropics, n (%)	28 (27)	2 (13)	26 (30)	0.192
Use of IABP, n (%)	12 (12)	0 (0)	12 (14)	0.128
Use of ACEI or ARB, n (%)	57 (55)	10 (67)	47 (53)	0.340
Use of beta blocker, n (%)	21 (20)	4 (27)	17 (19)	0.514
Use of diuretic, n (%)	40 (39)	2 (13)	38 (43)	0.028*
Temporal pacemaker, n (%)	10 (10)	0 (0)	10 (11)	0.169
Cardioversion, n (%)	6 (6)	0 (0)	6 (7)	0.297
ICU hospitalization, n (%)	63 (61)	5 (33)	58 (66)	0.017*
ICU hospitalization (days)^†	2.0 (0–5.0)	1.0 (0–2.0)	3.0 (0–6.5)	0.005*
Hospitalization (days)^†	14.0 (7.0–28.0)	3.0 (3.0–9.0)	17.0 (8.0–32.0)	0.001*
In-hospital cardiac mortality, n (%)	0 (0)	0 (0)	0 (0)	—
Cardiac mortality during followup, n (%)	0 (0)	0 (0)	0 (0)	—
Mortality during followup, n (%)	14 (14)	0 (0)	14 (16)	0.097
Recurrence, n (%)	0 (0)	0 (0)	0 (0)	—

IABP: intra-aortic balloon pump; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; ICU: intensive care unit.
^†Presented as median (inter-quartile range).
*Significant finding.